Berlin

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• HIV5 trials
• Asthma1 trial
• Colorectal cancer1 trial
• COPD1 trial
• Head and neck cancer1 trial
• Hepatitis B1 trial
• Lung cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 37 trials
• Phase 24 trials

Status

• Active, not recruiting8 trials
• Completed4 trials

Lead sponsor

• GlaxoSmithKline7 trials
• ViiV Healthcare5 trials

Running trials

• Active, not recruiting

  A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

  NCT06537414· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

  NCT06062420· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

  NCT05723562· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

  NCT04915755· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

  NCT03299049· Phase 3· ViiV Healthcare· Source

• Active, not recruiting

  Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

  NCT02951052· Phase 3· ViiV Healthcare· Source

• Active, not recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

  NCT02938520· Phase 3· ViiV Healthcare· Source

• Active, not recruiting

  Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

  NCT02362503· Phase 3· ViiV Healthcare· Source

Closed trials

• Completed

  Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04719832· Phase 3· GlaxoSmithKline· Source

• Completed

  Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

  NCT04133909· Phase 3· GlaxoSmithKline· Source

• Completed

  Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

  NCT03739710· Phase 2· GlaxoSmithKline· Source

• Completed

  Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany

  NCT03754803· ViiV Healthcare· Source